GHK-Cu Is Now the Fastest-Growing Peptide in Consumer Search. The Evidence Hasn’t Caught Up.
GHK-Cu is now the fastest-growing peptide in consumer search—and the gap between interest and evidence has never been wider. Somewhere […]
The FDA Just Scheduled the Most Consequential Peptide Meeting in Years
The FDA peptide reclassification process took its most significant step forward on Tuesday. On Tuesday, the FDA announced it will
Retatrutide Phase 3: 28.7% Weight Loss, Osteoarthritis Relief, and a Safety Signal Worth Watching
Retatrutide just delivered Phase 3 results that redefine what’s possible in pharmaceutical weight loss—and raised new questions about tolerability. Eli
Researchers Scanned 400,000 Reddit Posts for GLP-1 Side Effects. Here’s What Doctors Are Missing.
A landmark study on GLP-1 side effects just surfaced symptoms that clinical trials may be missing. A team at the
Peptides Are Having a Moment
Peptides Are Having a Moment April 8, 2026 In the first week of April 2026, something happened that doesn’t normally
Viking Therapeutics, Amgen, and the Next-Generation Obesity Pipeline
While Eli Lilly consolidates its lead in the obesity therapeutics market, a second wave of companies is advancing candidates that
A Patient Chose BPC-157 Over a Statin. A STAT News Physician Asks Why.
A physician writing in STAT News on April 3 described a patient who refuses to take a statin — a drug
FDA Approves Foundayo (Orforglipron) — First Oral GLP-1 for Weight Loss With No Food or Water Restrictions
The FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 receptor agonist for
NPR Investigates Unregulated Peptides Sold Directly from Chinese Factories
An NPR/WBUR investigation published March 24 documented the pipeline through which unregulated peptides move from Chinese manufacturing facilities to American
Retatrutide Phase 3 Delivers 26% Weight Loss — But a New Safety Signal Emerges
Eli Lilly’s retatrutide — the first triple-hormone-receptor agonist (GLP-1, GIP, and glucagon) — posted striking Phase 3 results from the TRIUMPH program,